What Is Intravascular Lymphoma?

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen independent categorical types and subtypes of cancers of the lymphatic system. It is also known as intravascular large B-cell lymphoma and was previously known as angiotropic lymphoma.

Intravascular lymphoma (IVL) is a very rare sub-subtype of a very common subtype of non-Hodgkin's lymphoma, extranodal diffuse large B-cell lymphoma. What happens in IVL is that cancerous lymphocytes, which are distorted in shape and size compared to healthy lymphocytes, will pile up in the associated blood vessels, causing swelling and distention.

Affecting patients at middle-age and older, as an extranodal disease Intravascular lymphoma will affect organs and this disease can affect virtually any organ in the body. Unlike most lymphomas, intravascular lymphoma does not commonly involve the lymph nodes. This also holds true for the spleen.

While the vast majority of cases of intravascular lymphoma are of B-cell lineage, rarely the disease will affect the T-cells.

Symptoms of intravascular lymphoma

Because IVL is an extranodal disease, this means that symptoms will vary, depending on the extranodal organ that is being affected. Generalized symptoms may include fatigue, but perhaps the key clinical feature of IVL is vascular obstruction and subsequent edema depending on where this is occurring and what organ(s) is affected.

The extranodal sites most frequently involved in IVL are the skin and the central nervous system, but it has also been known to affect the kidneys, lungs, and GI tract, among other organs.

Diagnosing intravascular Lymphoma

IVL is notorious for presenting itself in various and misleading ways, making diagnosis extremely difficult, especially since it is so rare that doctors are not typically looking for it. Consequently, until recently a diagnosis of intravascular lymphoma has most often been made post-mortem, after the patient has already died.

However, as pathology techniques have improved, along with imaging techniques, the diagnosis of intravascular lymphoma is being made more and more often before the patient dies and in time to offer therapeutic intervention.

Treatment and prognosis of intravascular lymphoma

Because it has traditionally been overlooked or diagnosed too late, and because of its aggressive nature, the mortality rate of intravascular lymphoma is very high. When the disease is diagnosed early, therapeutic intervention with chemotherapy has shown to be successful, even curative in some cases.

Sources

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap